Klotz, Kerstin A.
Grob, Daniel
Schönberger, Jan
Nakamura, Lea
Metternich, Birgitta
Schulze-Bonhage, Andreas
Jacobs, Julia
Funding for this research was provided by:
Universitätsklinikum Freiburg
Article History
Accepted: 30 September 2021
First Online: 22 October 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. This research received no specific grant from any funding agency in the public, commercial, or nonprofit sector.
: Kerstin A. Klotz has received honoraria for lectures and advice from EISAI, GW Pharmaceuticals, and Zogenix. Jan Schönberger has received an honorarium for a lecture and advice from GW pharmaceuticals. Andreas Schulze-Bonhage has received honoraria for lectures and advice from BIAL, EISAI, Precisis, and UCB. Daniel Grob, Lea Nakamura, Brigitta Metternich, and Julia Jacobs have no conflicts of interest that are directly relevant to the content of this article.
: The trial was approved by the ethics committee of the Albert-Ludwigs-University Freiburg (397/17).
: All patients or their parents/legal representatives provided written informed consent and assent according to patients’ physical and mental capability before trial onset.
: Not applicable.
: The dataset supporting the conclusions of the manuscript will be made available by the authors, to any qualified researcher, without breaching participant confidentiality.
: Not applicable.
: KAK designed and conceptualized the study, played a major role in the acquisition of data, analyzed the data, and drafted the manuscript for intellectual content. DG had a major role in the acquisition of data. JS and LN had a major role in the acquisition of data and revised the manuscript for intellectual content. BM and ASB interpreted the data and revised the manuscript for intellectual content. JJ provided advice in conceptualizing the study, interpreted the data, and revised the manuscript for intellectual content. All authors read and approved the final version of the manuscript and agreed to be accountable for the work.